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Backgrounds. Pyogenic liver abscess is a rare disease whose management has shifted toward greater use of percutaneous drainage.
Surgery still plays a role in treatment, but its indications are not clear. Method. We conducted a retrospective study of pyogenic
abscesscasesadmittedtoouruniversityhospitalbetween1999and2010andassessedthefactorspotentiallyassociatedwithsurgical
treatment versus medical treatment alone. Results. In total, 103 liver abscess patients were treated at our center. The mortality
was 9%. The main symptoms were fever and abdominal pain. All of the patients had CRP > 6g/dL. Sixty-nine patients had a
unique abscess. Seventeen patients were treated with antibiotics alone and 57 with percutaneous drainage and antibiotics. Twenty-
seven patients who were treated with percutaneous techniques required surgery, and 29 patients initially received it. Eventually,
43 patients underwent abscess surgery. The factors associated with failed medical treatment were gas-forming abscess (P = 0.006)
and septic shock at the initial presentation (P = 0.008). Conclusion. Medical and percutaneous treatment constitute the standard
management of liver abscess cases. Surgery remains necessary after failure of the initial treatment but should also be considered
as an early intervention for cases presenting with gas-forming abscesses and septic shock and when treatment of the underlying
cause is immediately required.
1.Introduction
Pyogenic liver abscess (PLA) remains a rare disease with a
high risk of mortality, up to 19% [1–13]. In recent years,
diagnosing PLA and the underlying cause of the abscess has
been made easier by modern imaging modalities. PLA man-
agement has also changed, with percutaneous drainage and
intravenous antibiotics being now considered safe and eﬀec-
tive [7, 8, 12]. Even though a nonoperative interventional
radiology approach has become the ﬁrst therapeutic choice
for PLA, surgical treatment is still necessary in some cases,
although its proper indications remain unclear. Indeed,
surgical drainage is associated with increased morbidity and
mortality and is often only used as a salvage procedure in
cases failed percutaneous treatment [10, 12]. The aim of our
s t u d yw a st or e t r o s p e c t i v e l ya n a l y z eo u rm o n o c e n t r i cF r e n c h
series of PLA cases and to reappraise the place of surgery in
modern PLA management using a recent occidental series.
2. Patients andMethods
All of the adult patients treated for a PLA from 1990 to 2009
in the Departments of Infectious Disease, Gastroenterology,
and Hepatobiliary Surgery at the University Hospital of Caen
were retrospectively reviewed. We excluded all abscesses
resulting from a fungal or amebic abscess, infected tumor,
or infected liver cyst from the study.
The clinical presentation, past medical history, and mi-
crobiological and radiological parameters were obtained
from each patient’s record. This data included age, gender,2 HPB Surgery
presenting symptoms, comorbidities, ASA score, underlying
etiology, presence of diabetes mellitus, BMI, presence of
malignancy, imaging studies focused on the size and num-
ber of abscesses, microbiological ﬁndings, and the abscess
components (ﬂuid, gas, walls). The size of the abscess was
deﬁnedasthelargestdiameterreportedonCT.Themicrobes
responsible for the PLA were also noted. The biological
parameters examined included hemoglobin and albumin
levels, white blood cell count, creatinine level, CRP, ﬁbrino-
gen, total bilirubin level, and liver enzymes. The etiology
of the abscesses was classiﬁed into four groups: group 1,
biliary; group 2, portal; group 3, cryptogenic; group 4, other
(iatrogenic, arterial).
The choice of initial treatment was based on the prefer-
ence of the attending physician. The treatments were clas-
siﬁed as antibiotics alone for 6 weeks (group A), antibiotics
andpercutaneoustreatment(percutaneousneedleaspiration
(PNA) or drainage) (group AP), or surgical treatment (after
percutaneous drainage or not) (group AS). Failure of antibi-
otic or percutaneous treatment was deﬁned as persistent
infection after 3 to 5 days of the chosen therapy. Treating
the cause of the abscess was also recorded. Cure was deﬁned
as resolution of the infectious syndrome and symptoms at 2
months after initiating treatment.
The factors associated with failure of medical treatment
and mortality were studied to evaluate the indications for
early aggressive surgical treatment of patients presenting
with such factors. Septic shock was deﬁned as a state of
combined hypotension, tachycardia, polypnea, oliguria, and
altered mental status with a temperature over 38◦Co ru n d e r
36◦C. Mortality was deﬁned as death within 30 days or
during the concurrent hospital admission.
The data were compiled and analyzed using the SAS v.9.1
software. The continuous numeric data are displayed in
tables as means and the categorical data as percentages. The
categorical data were compared between groups using either
the χ2 or Fisher’s exact tests. Student’s t-test was used to
compare continuous data. P< 0.05 was accepted as signiﬁ-
cant. Univariate analyses were performed. ROC curves were
used to describe the predictive value of certain biological
parameters for mortality.
3. Results
From January 1990 to December 2008, a total of 103 con-
secutive patients were treated in the Departments of Hep-
atobiliary Surgery, Gastroenterology, and Infectious Disease
at the University Hospital of Caen, France. Fifty-seven were
male,andtheyhadameanageof64years.Fiftypatientswere
ASA II, and the most common comorbidities were active
smoking (22.3%) and diabetes mellitus (17.5%). The most
common presenting symptoms were hyperthermia (93.0%)
and abdominal pain (73.0%). Fourteen patients presented
with septic shock, and two patients had an intraperitoneal
abscess rupture. The demographic clinical and biological
data are reported in Table 1.
All of the biological parameters were representative of a
chronic inﬂammatory state. CRP was elevated in all cases,
and its level was over 100mg/L in 90 patients. We found
Table 1: The demographic, clinical, and biological data.
Age 64,4 15–94
Sex ratio (M:F) 1,24 1,24
Number of patients Percentage
BMI > 30 16/103 15.50%
ASA > 2 68/103 66%
Immunosuppression 2/103 1.90%
Chronic alcohol intake 16/103 15.50%
Clinical presentation
Fever > 38,5◦C 95/102 93%
Abdominal pain 74/101 73%
Chills 47/86 54%
Vomiting 31/102 30%
Jaundice 13/102 12.60%
Hepatomegaly 8/102 7.70%
Biology
CRP > 6mg/L 103/103 100%
Fibrinogen > 4,5g/L 87/91 95.60%
Albumin < 37g/L 97/103 94.30%
Proteins < 60g/L 32/95 33.60%
Leukocytes <4000/>10000 74/96 74.70%
Hemoglobin < 12g/dL 66/99 66.60%
Platelets <150,000/>500,000 27/96 28.10%
GGT > 38UI 89/95 93.60%
ALAT > 34UI 87/95 60.40%
Bilic > 3μmol/L 86/103 83.5%
Table 2: The pathogens identiﬁed in the liver abscesses.
Percentage of patients
Pathogen identiﬁed 71.80%
E. coli 39.20%
Klebsiella 9.50%
Streptococcus 36.50%
Fusobacterium 6.70%
Staphylococcus 5.40%
Multiple 35.10%
hypoalbuminemia (<37g/L) in 97 patients. The microbe
responsible could be identiﬁed in 71.8% of the cases and
was most frequently Escherichia coli. This bacterium was
isolated in 76.3% of the abscess cultures but in only 41.6%
of blood cultures. Anaerobic isolates were found in 24% of
the patients. Table 2 shows an overview of pathogens found
in PLA patients and correlates the pathogen found with the
abscess etiology.
The imaging characteristics are reported in Table 3.M o s t
of the abscesses were unique (68.3%), measured more than
5cm (70.7%) and were located in the right liver (58.2%).
Nine percent of patients had gas-forming abscesses. Twenty-
nine patients (28.1%) presented with a right pleural eﬀusion
on admission. The most common cause of liver abscess was
biliary tract disorder (45.6%), followed by portal origins
(25.2%). Despite thorough investigations, no cause couldHPB Surgery 3
Table 3: The imaging characteristics.
Number Percentage (%)
Number
Unique 69/102 68.30%
Multiple 27/102 26.70%
Diﬀuse form 6/102 6%
Size (max)
<5cm 30/103 30.9
5–10cm 46/103 44.6%
>10cm 27/103 24.5%
Localization
Right lobe 60/103 58.20
Left lobe 25/103 24.20%
Bilobar 18/103 17.40%
Walls 36/103 36%
Gas-forming abscess 9/100 9
be found in 18.4% of the cases. The detailed origins of the
abscesses are reported in Table 4.
The treatment consisted of antibiotics alone in 16.5% of
the cases (group A), as compared to 55.4% with antibiotics
and percutaneous treatment (group AP). Overall 41.7% of
the patients underwent surgery for PLA treatment (group
AS); 28.1% of these cases represented the initial treatment,
and 26% were in response to failure of nonsurgical therapy
(Table 5).
In group A, 17 patients who were successfully treated
with antibiotics alone presented with multiple small
abscesses (median size: 3.7cm). The mean hospital stay was
19. 8 days with a mean duration of treatment of 44, 64 days.
Of these patients, 70% were considered cured at 2 months
after the initial treatment. Two patients died, one of sepsis
and one of the ´ evolution of an underlying cancer.
In group AP, 57 patients were treated with antibiotics
and interventional radiology. These treatments failed in
14 patients, who needed additional surgical drainage. The
successful initial percutaneous treatment cases involved 26
patients who underwent percutaneous drainage, 7 who
underwent percutaneous needle aspiration only, and 6 who
required drainage after having had a PNA. One patient
needed two PNAs. The PLAs were unique in 72.5% of the
cases, with a mean size of 8.7cm. Walls could be found
on imaging in 55% of the patients. The pathogen was
identiﬁed in 77.5% of the patients, and antibiotic treatment
was administered for a total of 50 days. The percutaneous
drain was left in place for a mean of 11 days. The mean
hospital stay was 25.8 days, and 65% of the patients had
recovered at 2 months. Five patients subsequently died.
In group AS, 43 patients underwent surgical treatment.
Seventeen (39.5%) of the patients required surgery after
antibiotic therapy. Twenty-nine percent of these patients
were diabetic. The PLAs were mostly unique (68.3%); the
mean size was 4.5cm, which is slightly larger than the PLAs
successfully treated by antibiotics alone. Seventeen percent
of these patients presented with septic shock on admission.
Most of the abscesses originated from biliary tract disorders
(76%). All of the patients were cured, except for one patient
who died.
Fourteen (32.5%) group AS patients required surgery
after failure of percutaneous treatment. Their abscesses were
unique in 57% of the cases and measured more than 8cm.
A total of 35% of the abscesses were of biliary origin, and
35% were of portal origin. Surgery resolved all symptoms
and helped ﬁnd the cause of the abscess in one-third of the
patients.
Twelve group AS patients (28%) underwent surgery as
the initial treatment. One-third were diabetic. Eighty-three
percentoftheabscesseswereunique,withameansizeof9,14
centimeters. Two presented with intraperitoneal rupture.
Twenty-ﬁve percent presented with septic shock. Sixty-seven
percent of the PLAs resulted from biliary tract disorders.
One patient died of pulmonary embolism 5 days after the
surgery. All of the other patients had recovered completely
by 2 months. Mean hospital stay was 37 days.
Of the patients needing surgery, 79% underwent simple
drainage of the abscess cavity with large abdominal drains.
Hepatectomy was necessary in 21% of the patients; 2
underwent major liver resections, and the majority only
required minor liver resection, mainly segmentectomies.
The causes of the abscesses were treated in 80% of the
cases. In total, 64.6% of the patients required a surgical pro-
cedure to treat the cause, which was performed after resolv-
ing the PLA in 27.5% of the patients. Forty-two patients
underwent surgical treatment of the PLA cause during the
same hospital stay; this treatment consisted of 21 cholecys-
tectomies, 8 colectomies, 4 appendectomies, 3 choledocoje-
junostomy resections, 1 gastrectomy, and 1 nephrectomy.
Intheunivariateanalyses,theonlysigniﬁcantfactorasso-
ciated with the surgical PLA treatment was BMI (26.8 versus
24.2; P = 0.03). Diabetes mellitus and septic shock were
more likely to be associated with surgery, but neither reached
signiﬁcance (P = 0.08 for both). The factors associated with
failed medical treatment and requiring surgical therapy were
gas-forming PLA (P = 0.006) and severe sepsis or septic
shock (Table 6).
The overall mortality was 8.7%. Four men and 5 women,
with a mean age of 72 years, died during the study period.
Five patients died of causes directly related to the PLA, and
4 died of thromboembolic complications or of cancer evolu-
tion. Severe sepsis and septic shock were the most common
causes of death.
In the univariate analyses, the factors associated with
mortality were a high ASA score (P = 0.02), neoplastic
PLA origin (P = 0.047), and right pleural eﬀusion (P =
0.018). According to the χ2 test, however, the PLA cause was
not signiﬁcantly associated with mortality. The ROC curves
constructed for the albumin level and the hemoglobin level
(chosen as a sign of severity of the sepsis) showed that an
albumin below 21g/L predicted mortality with a sensitivity
of 60% and a speciﬁcity of 80%. A hemoglobin level below
9,5g/dL predicted mortality with a low sensitivity (40%) but
a high speciﬁcity (90%).
4. Discussion
This is the ﬁrst monocentric French PLA series concerning
since 1988. The series reported in the literature after 19884 HPB Surgery
Table 4: The origin of liver abscesses.
Etiology Percentage
(%) Benign lesions Underlying cancer
Biliary 45.60% 12.6% cholecystitis
12.6% dysfunctional hepaticojejunostomy 4.8%
Portal 25.20% 14.5% colic diverticulitis 2.8%
Arterial 5.80% dental abscesses
Cryptogenic 18.40%
Table 5: The pyogenic liver abscesses treatments used.
No. of patients
Group A: antibiotics 17
Group AP: percutaneous treatment 57
Group AS: surgery 43
Table 6: Surgical versus medical treatment.
No surgery Surgery P
BMI 24.2 25.8 0.25
ASA 2.01 2.24 0.16
Diabetes 9.40% 20.69% 0.15
Jaundice 13.20% 1.70% 0.74
Anemia 67.90% 62.90% 0.66
Hyperleukocytosis 79.50% 71.40% 0.42
Hypoalbuminemia 97.70% 96.30% 0.72
Number 1.33 1.31 0.78
Size 7.04 7.54 0.56
Walls 48.08% 32.14% 0.16
Gas-forming PLA 1.80% 21.40% 0.006
Pleural eﬀusion 22.60% 31.03% 0.41
Septic shock 3.70% 24.10% 0.008
have mainly been from Asian countries, with the largest
series (483 patients) being reported by Chou et al. in 1997
[1].
Our series of 103 PLA patients found epidemiology that
was similar to that of the other series (Table 7), with a
slight male predominance. A PLA diagnosis was associated
with certain clinical and imaging features, with fever and
abdominal pain being the most common (Table 7). In our
series, the microbiological isolates found in cultures were
diﬀerent from those reported in Asian studies; the most
common isolates were E. coli and Streptococcus spp., whereas
Klebsiella pneumoniae is often the second-most common
PLA pathogen isolated in Asian series [1, 8, 10–12, 14–16].
Indeed, a recent Spanish series of 84 patients reported that
Streptococcus spp. was by far the most commonly found
(40.5%) microbe [17].
As for diagnosing PLA, two biological criteria emerge
fromthisseries.Theprincipal(100%)abnormalbiochemical
ﬁnding was an elevated CRP. This ﬁnding is interesting
because it is the only highly sensitive indicator and because
it was over 100mg/L in 87% of the cases. Leukocytosis,
althoughreportedelsewhereasbeing themost commonPLA
ﬁnding, was only present in 74.7% of the cases in our series
[1, 5, 8, 10].
This series conﬁrms that biliary tract diseases are the
major cause of PLA [3, 8, 12, 16, 18, 19]. Portal phlebitis
from a bowel infection was the second-most frequent cause,
at 25.2%. This etiology was the most commonly found in
ap r e v i o u ss t u d y[ 20]. Interestingly, our series found fewer
cryptogenicPLAsthanpreviousseries.Indeed,only18.4%of
the PLAs were cryptogenic, as compared to more than 40%
in earlier studies [8, 10, 15]. This lower percentage may have
been due to the more extensive etiological research that used
more precise and sensitive imaging, as has been suggested by
Cohen et al. [21], who found that only 10% of abscesses to
be cryptogenic. A higher rate of identiﬁed pathogens is also
helpful in determining the PLA etiology [22].
Most of our patients (55%) were treated using a com-
bination of antibiotics and percutaneous treatment (aspira-
tion or drainage). This combination is currently the PLA
treatment of choice because it is a safe and eﬀective option
that oﬀers a low-risk approach to these often critically
ill patients [4, 10, 11, 19, 23–27]. However, percutaneous
therapy frequently fails, with rates ranging from 15% to 36%
(similar to the 26% rate found in our series) [1, 11, 23, 28].
The causes of failed PLA treatment include multiple
abscesses with multiple loculations [1, 12], large abscesses
(>5cm) containing thick pus with necrotic tissue, issues
directly linked to the drainage catheter (blockage, slippage,
and chest empyema due to transpleural drainage), and
the technical diﬃculties associated with performing safe
drainage. In our experience, there were signiﬁcantly more
gas-forming abscesses (P = 0.006) and patients in septic
shock (P = 0.02) among the cases of percutaneous treatment
failures. Our study represents the ﬁrst occasion that these
two criteria have been linked to failed medical treatment.
Chou et al. [6] speciﬁcally studied gas-forming abscesses
and concluded that they are more severe, often presenting
with septic shock and are associated with higher mortality
than non–gas-forming abscesses (27.7%). Their treatment
algorithmstartswithmandatorypercutaneoustreatmentbut
does not recommend surgery as an initial treatment.
As in other series, we found that PLAs linked to biliary
tract disorders failed to respond to medical therapy more
often than other PLAs. Indeed, eﬀective biliary drainage is
essential to treating such PLAs, and PLA drainage alone is
not enough to achieve a cure [29–31].
As a result of the large variety of medical and inter-
ventional treatments, surgery is usually only considered in
cases of failed percutaneous treatment; therefore, the twoHPB Surgery 5
Table 7: A PLA literature review.
Series Country Year Age
Male
patients
%
Number of
patients Fever % Abdominal
pain %
Unique
PLA %
Right
lobe % Gas % Mortality
%
Farges (1) France 1998 51 47 46 75 55 ? ? 24
Branum (2) USA 1990 53 52 73 78 80 59 70 19
Stain (3) USA 1991 47 59 54 45 14 57 59 2
Mischinger (4) Austria 1994 51 65 46 80 54 68 74 17
Chou (5) Taiwan 1995 56 58 424 92 55 70 65 20 16
Huang (6) USA 1996 55 57 153 67 89 52 63 31
Chu (7) Hong
Kong 1996 60 57 83 70 53 ? 69 18
Chou (13) Taiwan 1997 55 58 483 92 82 69 66 20 15
Yeh (8) Taiwan 1998 56 55 52 93 53 94 ? 10 21
Lee (9) Taiwan 2001 53 62 133 92 69 73 71 6
Alvarez (10) Spain 2001 60 62 133 90 40 87 73 14
Tan (11) Singapore 2005 60 58 80 ? ? 76 ? 4
Ferraioli (12) Italy 2005 61 61 148 ? ? ? ? 0
approaches can be considered complementary and not
competitive [4–6]. Surgery has indications for initial PLA
treatment and should not be considered only a secondary
therapeutic option in cases of failed percutaneous treatment.
Itiswidely acceptedthatsurgeryismandatory in caseswhere
these is abscess rupture into the peritoneal cavity. Surgery is
also necessary if drainage cannot be performed. In addition,
multiloculated abscesses are often better treated by surgery
that completely breaks down of all the loculations [12, 32].
Surgery is also discussed in other circumstances, depend-
ing on the mortality-associated factors involved. Some au-
thors agree that surgery should be the ﬁrst-line therapy in
casesofhighmortalityrisktoimprovethechancesofsurvival
in these critically ill patients [12, 28].
For these reasons, it is important to study the factors
linked to mortality. Mortality has improved in recent years
thanks to more rapid diagnosis, more eﬀective antibiotics,
and the development of percutaneous procedures. Our series
had an overall mortality rate of 8,7%, which is on the low
end of the rates reported in the literature (0–46%) (Table 7).
The factors linked to mortality in our series’ univariate
analyses were a high ASA score (P = 0.02), a malignant PLA
origin and the presence of a pleural eﬀusion (P = 0.018).
The pleural eﬀusion is an interesting factor, as has been
previously reported [33], and is probably secondary to the
importance of right upper quadrant sepsis. The other factors
thathavebeenlinkedtomortalityareseveresepsisandshock,
high leukocytosis, low hemoglobin, increased creatinine,
elevated blood urea nitrogen and hypoalbuminemia [11,
17]. Gas-forming abscesses have also been independently
associated with mortality [6, 14, 34].
The general condition of the patient is an important fac-
tor that aﬀects mortality, although it is diﬃcult to evaluate.
Patient health indices have been developed in consultation
with anesthesiologists, and statistical analyses (univariate
and multivariate) have reached diﬀerent conclusions. Some
teams have reported that an APACHE score >15 is sig-
niﬁcantly associated with mortality [5, 14, 16], and some
authors agree that these patients are better served by surgical
exploration[1,8].Similarly,Loketal.foundinarecentseries
that the existence of >2 comorbid illnesses was associated
with mortality in a univariate analysis [15].
Therefore, two contrasting perspectives on PLA can be
noted. One has been expressed by Mishinger et al., who
maintain that patients with high mortality risks based on
their APACHE score should not undergo surgery as a ﬁrst-
line treatment but only percutaneous drainage to attempt
to resolve the PLA by the least invasive methods possible
[5]. Their indications for surgery consist of failed medical
treatment or PLA ruptures into the peritoneal cavity. By
contrast, our team and others [16, 35]h a v ep r o p o s e dam o r e
aggressive therapy, especially if the patient is critically ill
or has high mortality risk. This position is based on the
percentage of failed percutaneous drainage attempts, which
was 26% in our series and 27,8% for Tan et al. [12]. Such
a high failure rate for critically ill patients implies delayed
eﬀective therapy, which increases the mortality rate [10, 35].
We think that an aggressive approach, such as an initial sur-
gicalprocedure,shouldbethetreatmentofchoiceinpatients
with poor prognosis or failure of percutaneous drainage,
especially given that the mortality rate after surgery, which
was high in the 1980s, has decreased as hepatic surgery has
improved. Indeed, in our series, we observed a 0% surgical
mortality rate.
The experience accumulated through these diﬀerent
series helps to distinguish two types of situations leading
to surgical PLA management. The ﬁrst set of indications
is linked to the risk of failed percutaneous treatment and
include gas-forming abscesses, multiloculated abscesses, and
septic shock at presentation. The second set of indications
is linked to factors associated with high mortality: an
elevated ASA score, an APACHE score > 15, severe sepsis6 HPB Surgery
(leukocytosis, albumin < 21g/dL, hemoglobin < 9,5g/L),
pleural eﬀusion, and a malignant PLA origin.
In conclusion, even though percutaneous treatment
combined with antibiotics is a safe and eﬀective PLA treat-
ment, PLA remains a surgical concern. We suggest that crit-
ically ill patients with severe sepsis associated with gas-
forming or multiloculated abscesses on imaging should un-
dergo surgery as a ﬁrst-line treatment. Surgery is particularly
appropriate for patients with low albumin and hemoglobin
and a high ASA score. Patients with a right pleural eﬀusion
should also be considered at high risk for mortality and
therefore likely to beneﬁt from aggressive therapy.
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